Commercializing biotechnology in China
I recently had the opportunity to conduct a brief interview with Mireille Gingras, Ph.D. President and CEO of HUYA Bioscience […]
General Biotechnology, Guest content
Guest content
General Biotechnology, Guest content
Contract research helps keep drug pipeline flowing
Guest content from Turner Investment Partners‘ Heather Flick McMeekin, Frank Sustersic, Vijay Shankaran, and Theresa Hoang: Contract research helps keep
Contract research helps keep drug pipeline flowing Read Post »
General Biotechnology, Guest content
Background: The Clinical and Translational Science Awards Consortium (CTSA program)
Guest content from Christopher Starr: After years of confusion and neglect, translational research is now becoming institutionalized. Citing the barriers
Background: The Clinical and Translational Science Awards Consortium (CTSA program) Read Post »
General Biotechnology, Guest content
Why the market does not like Flurizan
Guest content from Nicolaj H. Nielsen, managing director of Biostrat. A case-study on the recent licensing-deal between Myriad and Lundbeck:
General Biotechnology, Guest content
Six Pitfalls to Avoid in Supplier Management
Guest content from John Avellanet, managing director and principal of Cerulean Associates: Managing suppliers is fraught with challenges. Rare is
General Biotechnology, Guest content
Seeing the Field
Guest content from Sandy Graham, managing partner at Sequoyah Associates: Can you “see the field” of opportunity? Have your clearly
General Biotechnology, Guest content
Generic Biologics: How to Compete
Guest content from John Avellanet, managing director and principal of Cerulean Associates: Follow-on biologics are a foregone conclusion in the
General Biotechnology, Guest content
FDA Enforcement Trends: 2007-2008
Guest content from John Avellanet, managing director of Cerulean Associates: The US Food and Drug Administration (FDA) intends to increase
General Biotechnology, Guest content
Expanding the bandwidth of life science investments: Increasing investment viability
Guest content Contributed by Jayme Norrie, Chief Strategic Officer, Incite World From what we have experienced, angel investors are shoring
Expanding the bandwidth of life science investments: Increasing investment viability Read Post »
General Biotechnology, Guest content
Offshoring and U.S. Biotech Labor Shortages
Guest content contributed by Agnes Shanley, Editor in Chief, Pharmaceutical Manufacturing Every day we read about severe shortages of skilled